0001354457-18-000107.txt : 20180419
0001354457-18-000107.hdr.sgml : 20180419
20180419101301
ACCESSION NUMBER: 0001354457-18-000107
CONFORMED SUBMISSION TYPE: 25-NSE
CONFIRMING COPY:
PUBLIC DOCUMENT COUNT: 2
FILED AS OF DATE: 20180419
DATE AS OF CHANGE: 20180419
SUBJECT COMPANY:
COMPANY DATA:
COMPANY CONFORMED NAME: INNOVATE BIOPHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0001551986
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 25-NSE
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37797
BUSINESS ADDRESS:
STREET 1: 8480 HONEYCUTT ROAD
STREET 2: SUITE 120
CITY: RALEIGH
STATE: NC
ZIP: 27615
BUSINESS PHONE: 919-275-1933
MAIL ADDRESS:
STREET 1: 8480 HONEYCUTT ROAD
STREET 2: SUITE 120
CITY: RALEIGH
STATE: NC
ZIP: 27615
FORMER COMPANY:
FORMER CONFORMED NAME: Monster Digital, Inc.
DATE OF NAME CHANGE: 20150930
FORMER COMPANY:
FORMER CONFORMED NAME: Tandon Digital, Inc.
DATE OF NAME CHANGE: 20120611
FILED BY:
COMPANY DATA:
COMPANY CONFORMED NAME: The Nasdaq Stock Market LLC
CENTRAL INDEX KEY: 0001354457
IRS NUMBER: 521165937
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 25-NSE
BUSINESS ADDRESS:
STREET 1: One Liberty Plaza
CITY: New York
STATE: NY
ZIP: 10006
BUSINESS PHONE: 301-978-4144
MAIL ADDRESS:
STREET 1: Office of General Counsel
STREET 2: 805 King Farm Blvd.
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
25-NSE
1
primary_doc.xml
X0203
0001354457
The Nasdaq Stock Market LLC
0001551986
INNOVATE BIOPHARMACEUTICALS, INC.
001-37797
2655 Park Center Drive, Unit C
Simi Valley
CA
CALIFORNIA
93065
8059554190
Warrant
17 CFR 240.12d2-2(b)
Amy Horton
Hearings Advisor
2018-04-19
EX-99.25
2
inntwdelistreason.txt
Delisting Determination,The Nasdaq Stock Market, LLC,
April 19, 2018, Innovate Biopharmaceuticals, Inc. The Nasdaq
Stock Market, Inc. (the Exchange) has determined to remove
from listing the warrant of Innovate Biopharmaceuticals, Inc.
(the Company), effective at the opening of the trading
session on April 30, 2018. Based on review of information
provided by the Company, Nasdaq Staff determined that the
Company no longer qualified for listing on the Exchange
pursuant to Listing Rule 5550(b)(1). The Company was notified
of the Staffs determination on October 19, 2017.
The Company appealed the determination
to a Hearing Panel. Upon review of the information provided
by the Company, the Panel issued a decision dated
December 11, 2017, granting the Company continued listing
pursuant to an exception that included several milestones
that the Company was required to meet, towards the toal
of regaining compliance with Listing Rules 5550(b)(1), 5550(a)(2),
5555(a)(2) and 5620(a). The Company met the exception milestones
for its common stock, however, the Company was
unable to meet the exception milestones for the warrant.
On February 27, 2018, the Panel issued a final compliance
determination for the common stock and notified the
Company that trading in the Companys
warrant would be suspended on March 5, 2018.
The Company did not request a review of the Panels decision
by the Nasdaq Listing and Hearing Review Council. The
Listing Council did not call the matter for review.
The Panels Determination to delist the Companys warrant
became final on March 5, 2018.